© 2021 KOSU
Play Live Radio
Next Up:
0:00
0:00
Available On Air Stations

How Medicare Might Decide To Cover Biogen's New Alzheimer's Drug

When the Food and Drug Administration last month approved a new Alzheimer’s drug made by Biogen, even though there’s not sufficient evidence the drug works, insurance companies began questioning whether they should cover the cost of the drug.

Most patients that might be prescribed it are older Medicare patients, putting extra pressure on Medicare to decide if and how it should cover the drug.

Host Robin Young talks to Rachel Cohrs, a Washington correspondent for our partners at STAT, the health and medicine publication.

This article was originally published on WBUR.org.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Hey! Did you enjoy this story? We can’t do it without you. We are member-supported, so your donation is critical to KOSU's news reporting and music programming. Help support the reporters, DJs and staff of the station you love.

Here's how: